Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 34 Melanoma 13 Carcinoma, Hepatocellular 13 Neoplasm Metastasis 12 Lung Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 9 Neoplasms 9 Esophageal Neoplasms 9 Colorectal Neoplasms 6 Esophageal Squamous Cell Carcinoma 5 Breast Neoplasms 5 Recurrence 4 Rectal Neoplasms 4 Brain Neoplasms 4 Uterine Cervical Neoplasms 3 Triple Negative Breast Neoplasms 3 Sarcoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Pancreatic Neoplasms 3 Liver Neoplasms 3 Head and Neck Neoplasms 3 Cholangiocarcinoma 3 Carcinoma, Renal Cell 3 Stomach Neoplasms 2 Small Cell Lung Carcinoma 2 Radiation Pneumonitis 2 Prostatic Neoplasms 2 Pathologic Complete Response 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neuroblastoma 2

Interventions

pembrolizumab 10 Nivolumab 9 Ipilimumab 4 avelumab 3 Neoadjuvant Therapy 3 toripalimab 2 sintilimab 2 durvalumab 2 atezolizumab 2 Specimen Handling 2 Immune Checkpoint Inhibitors 2 Celecoxib 2 tislelizumab 1 spartalizumab 1 relatlimab 1 regorafenib 1 fludarabine phosphate 1 fludarabine 1 dostarlimab 1 denileukin diftitox 1 danvatirsen 1 camrelizumab 1 XELOX 1 Taxes 1 Surgical Procedures, Operative 1 Radiation Dose Hypofractionation 1 Paclitaxel 1 Oxaliplatin 1 Megestrol Acetate 1 Medroxyprogesterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Turcot syndrome × Immunotherapy × Clear all

NCT07259473 2026-01-07

Pre-CATALIS

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting

Turcot syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡